We are pleased to announce coming launch of our new group of products, the miREIA kits for the quantitation of microRNA. The assay can be run on common immunoassay equipment, is compatible with standard clinical workflow, does not require amplification steps and results are obtained in less than three hours including miRNA profiling.
miREIA is a novel, immunoassay-based method of miRNA quantification which involves hybridization of miRNA isolated from a patient sample to complementary biotinylated DNA oligonucleotide probe. The DNA/RNA hybrids are then captured by a microtiter plate-immobilized monoclonal antibody specific to perfectly matched DNA/miRNA hybrids. Next steps are copying standard ELISA protocols.
hsa-miR-21-5p miREIA (Cat. No: RDM0001H)
hsa-miR-21-5p is a typical onco-miRNA frequently upregulated in solid tumors, most of the targets are tumor suppressors. Pancreatic, colorectal, gastric, brain, breast, lung, esophageal and hepatocellular cancers were often associated with miR-21-5p. It also plays role in the development of cardiovascular disease, acute myocardial infarction, pulmonary diseases and in regulation of immunological and developmental processes. Besides in tissues, recent evidence indicates the presence of miR-21-5p in various types of extracellular fluid, such as plasma, serum, CSF, saliva, gastric juice, pancreatic juice, sputum, and pancreatic cyst fluid.
Click to see the product brochure hsa-miR-21-5p miREIA kit
hsa-miR-93-5p miREIA (Cat. No: RDM0002H)
hsa-miR-93-5p is an onco-miRNA. Up-regulation of miR-93-5p is correlated with worse clinic-pathological features and can serve as an independent marker for poor prognosis in patients with non-small cell lung cancer. NSCLC cell proliferation, migration, and invasion were significantly stimulated by miR-93-5p upregulation and inhibited by miR-93-5p downregulation. miR-93-5p was also up-regulated in non-muscle invasive bladder cancer.Increased expression of circulating miR-93-5p in women with polycystic ovary syndrome may represent a novel non-invasive biomarker for diagnosis.
hsa-miR-145-5p miREIA (Cat. No: RDM0003H)
hsa-miR-145-5p might constitute a promising molecular marker for renal cell carcinoma classification and staging. It was described as a prognostic biomarker of overall survival in colon cancer but as a tumor suppressor gene in NSCLC metastasis.Low expression and plasma levels were found in patients with coronary artery disease and acute myocardial infarction.
hsa-miR-150-5p miREIA (Cat. No: RDM0004H)
hsa-miR-150-5p is linked with number of cancers. It was up-regulated in plasma of melanoma patients. Findings also demonstrate miR-150-5p as a putative novel biomarker of inflammatory active disease with the potential to be used for early diagnosis of multiple sclerosis. miR-150-5p is downregulated in children with tuberculosis. In aplastic anemia, levels of miR-150-5p were elevated, compared to healthy controls.miR-150-5p is expressed in the lymph nodes, spleen and thymus and it is highly up-regulated during lymphocyte maturation and down-regulated during the activation of mature B and T cells. In vivo studies show that miR-150 is released in the external environment after T cell activation and this may cause an increase of its blood levels during immune system stimulation.
hsa-miR-191-5p miREIA (Cat. No: RDM0005H)
hsa-miR-191-5p is dysregulated in many types of cancers (>20) and various other diseases like T2DM, pulmonary hypertension, Crohn’s and Alzheimer’s diseases. miR-191-5p regulates important cellular processes such as cell proliferation, differentiation and apoptosis. miR-191-5p is a promising disease biomarker and therapeutic target.
hsa-miR-451a miREIA (Cat. No.: RDM0006H)
hsa-miR-451a-5p levels are differentially expressed in patients with nonalcoholic fatty liver disease, rheumatoid arthritis, diabetes and several types of cancer including renal cell carcinoma, nonsmall lung cancer, osteosarcoma, esophageal adenocarcinoma and epithelial ovarian cancer. It is overexpressed in endometriotic lesion tissue and is also associated with endometriotic lesion survival.miR-451a-5p is expressed in the circulation, predominantly by erythrocytes, where i tis proposed to play a role in the differentiation and/or maturation of red blood cells.
- hsa-miR-15a-5p miREIA (Cat. No: RDM0007H)
- hsa-miR-16-5p miREIA (Cat. No: RDM0008H)
- hsa-miR-23a-3p miREIA (Cat. No: RDM0009H)
- hsa-miR-197-3p miREIA (Cat. No: RDM0010H)
- hsa-miR-320a miREIA (Cat. No: RDM0011H)
- hsa-miR-24-3p miREIA (Cat. No: RDM0012H)
- hsa-miR-142-5p miREIA (Cat. No: RDM0013H)
- hsa-miR-222-3p miREIA (Cat. No: RDM0014H)
- hsa-miR-223-3p miREIA (Cat. No: RDM0015H)
- hsa-miR-499a-5p miREIA (Cat. No: RDM0016H)
Comparison of miREIA and RT-qPCR
Reverse transcription reaction
Total time to result
Specific PCR cycler
Cost per sample
MicroRNAs (miRNAs) are new and promising potential biomarkers for diagnosis and prognosis of many diseases, which opens up a new field of goals and challenges for the BioVendor R&D team. Development of miRNA diagnostic assays is just the first step; our mission is to provide validated kits to measure individual miRNAs or diagnostically relevant miRNA “groups” supported with tools for standardized miRNA isolation, sample collection, and pretreatment.
MicroRNAs (miRNAs) are small, non-coding RNA molecules typically containing ~22 nucleotides found in human, animals, plants and some viruses which are playing an important regulatory role in the gene translation via silencing or degradation of target mRNAs. During the RNA silencing, miRNA functions as a complementary guide which binds with its target mRNAs, followed by action of AGO proteins family which works as effectors by recruiting factors that induce translational repression, mRNA deadenylation and mRNA decay. (Minju Ha, Nature Reviews, 2014)
MicroRNAs (miRNAs) are involved in virtually all physiologic processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation. The biogenesis and function of miRNAs are tightly regulated, and their dysregulation is often associated with pathology of many diseases such as cancer, heart disease or neurological disorders. Recently, the miRNA has been proposed as powerful biomarker for prediction of the diseases, treatment response or prediction of progression.
miRiam – miRNA immunoassay method
Novel method for miRNA quantification based on immunoassay. The novel method involves hybridization of miRNA isolated from patient sample to complementary biotinylated DNA oligonucleotide probe followed by monoclonal antibody detection of perfectly matched DNA/miRNA hybrids in several different arrangements and possible methods of visualization:
- Colorimetric – miReia – miRNA enzyme immunoassay
- Chemiluminescent – miRacle – miRNA antibody/capture luminometry
Click to see flyer about miRNA quantification
The assay arrangement:
- Classical ELISA format
- Array format
- Luminex beads format
Posters presented at scientific congressesMay/June 2017:
RNA society congress 2017 (Prague, Czech Republic) - poster miRiam – NEW TRENDS IN microRNA QUANTIFICATION
85th EAS congress 2017 (Prague, Czech Republic) - e-poster MicroRNA-BASED DIAGNOSTICS IN CARDIOVASCULAR DISEASE
GTCbio: Biomarker Summit Europe 2016 - 5th Biomarkers in Diagnostics Conference (Berlin, Germany) - poster miRiam – THE NEW INSIGHT INTO miRNA QUANTIFICATION
Do you want to know more?Click to download the poster on microRNA and Cardiovascular Disease.
Are you interested in receiving email about the news and events?Contact us at firstname.lastname@example.org.